1. My Clinical Approach to Robotic Radical Cystectomy
Radical cystectomy is one of the most complex operations in urology — it is not only about removing the bladder, but also about creating a new, functional pathway for urine. Many patients arrive anxious both about the operation itself and about life afterwards.
My role is to explain, based on the European Association of Urology (EAU) Guidelines on Muscle-invasive and Metastatic Bladder Cancer, what the real options are — including bladder preservation where it is safe — and what each patient should realistically expect.
In practice, I always follow:
- Complete staging (cystoscopy, TURBT, CT urography of the chest/abdomen/pelvis, laboratory work-up) before any treatment discussion.
- Presentation of all alternatives — radical cystectomy, trimodality bladder-preserving therapy (TMT) where appropriate — with the actual data behind each.
- Timely referral to multidisciplinary discussion, since delaying cystectomy beyond 3 months from diagnosis is associated with worse survival.
- Individualised decision on the type of urinary diversion and the possibility of organ preservation, depending on oncologic risk.
This guide is based on the EAU 2026 Guidelines on Muscle-invasive and Metastatic Bladder Cancer and published clinical literature — not on marketing material.
2. What Is Robotic Radical Cystectomy
Radical cystectomy is the complete surgical removal of the urinary bladder together with surrounding tissues, aiming for oncologic control of the disease. It always includes pelvic lymph node dissection and creation of a new urinary pathway, known as urinary diversion.
In the robotic variant (RARC – Robot-Assisted Radical Cystectomy), the operation is performed laparoscopically using a robotically-guided system, through small incisions in the abdominal wall.
- Removal of the urinary bladder (and usually adjacent organs, see section 6).
- Pelvic lymph node dissection, as an integral part of the operation.
- Creation of a urinary diversion (ileal conduit, orthotopic neobladder or ureterocutaneostomy).
3. Is It Really a “Robotic” Operation?
A robotically-guided system is indeed used, but that does not mean autonomous surgery.
The robot does not perform the operation autonomously. Every movement is controlled by the surgeon through the surgical console.
The surgeon sits at a dedicated console and controls every movement of the robotic arms in real time — the system makes no therapeutic decision on its own.
4. When It Is Indicated
The decision for radical cystectomy is individualised, following EAU guidelines, mainly in these situations:
Muscle-invasive Bladder Cancer (T2–T4a, N0, M0)
Radical cystectomy with pelvic lymph node dissection is the established treatment of choice, without delay beyond 3 months from diagnosis.
Very High-risk Non-muscle-invasive Disease
In selected patients with very high-risk disease, especially when the disease does not respond to intravesical BCG therapy (BCG-unresponsive/refractory/relapsing) or is extensive and cannot be controlled with TURBT and intravesical therapy.
Salvage Cystectomy
For patients who did not respond to bladder-preserving therapy and present with non-metastatic muscle-invasive recurrence.
Palliative Cystectomy (Rare)
In selected cases, for symptom control such as fistula, pain, or uncontrollable hematuria, when other options have been exhausted.
5. Alternative: Bladder-Preserving Therapy (Trimodality Therapy – TMT)
Radical cystectomy is not the only treatment option for muscle-invasive bladder cancer. Trimodality Therapy (TMT) – maximal transurethral resection of the tumour (TURBT) combined with concurrent chemoradiotherapy – is a recognised alternative in carefully selected patients.
Good candidates for TMT typically have:
- A solitary, unifocal cT2-T3a tumour.
- No extensive or multifocal carcinoma in situ (CIS).
- No hydronephrosis, or unilateral hydronephrosis only.
- Good baseline functional bladder capacity before treatment.
In propensity-matched studies, long-term oncologic outcomes (cancer-specific survival, overall survival) were similar between TMT and radical cystectomy in selected patients. However, TMT requires strict, lifelong bladder surveillance with cystoscopies, as recurrence may eventually require salvage cystectomy.
6. What Exactly Is Removed — Men & Women
In Men
Standard radical cystectomy includes the urinary bladder, the prostate, the seminal vesicles, the distal ureters and the regional lymph nodes.
In carefully selected patients with localised disease, without malignancy in the prostate/prostatic urethra/bladder neck, organ-sparing techniques (prostate-sparing, capsule-sparing, seminal-vesicle-sparing or nerve-sparing) can be considered to improve postoperative erectile function — only in carefully selected, well-informed patients, and without compromising oncologic safety.
In Women
Standard radical cystectomy includes the urinary bladder, the entire urethra, the adjacent portion of the vagina, the uterus, the distal ureters and the regional lymph nodes.
In carefully selected patients with a low risk of concomitant gynaecological malignancy, organ-preserving techniques (neurovascular bundle, vagina, uterus, ovaries) appear oncologically safe – always provided there is no disease in the organ being preserved.
The exact extent of surgery is always individualised based on anatomy, stage and preoperative biopsy findings — there is no single "standard" operation for every patient.
7. Pelvic Lymph Node Dissection
Pelvic lymph node dissection is an integral part of radical cystectomy — not an optional step. The standard template extends cranially to the common iliac bifurcation, with the ureter as the medial border, and includes the internal iliac, obturator and external iliac lymph nodes.
Large randomised trials (LEA, SWOG S1011) showed no survival benefit from more extended lymph node dissection compared with standard dissection, while extended dissection was associated with more severe complications and higher 90-day mortality. For this reason, a standard extent of lymphadenectomy is preferred in current clinical practice.
8. Systemic Therapy Before & After Cystectomy
Neoadjuvant Chemotherapy
In patients eligible for platinum, neoadjuvant platinum-based chemotherapy improves overall survival by approximately 8% at 5 years and is recommended before cystectomy.
Perioperative Chemo-immunotherapy (Durvalumab / NIAGARA)
In eligible patients with muscle-invasive disease (T2-T4a, cN0-1, M0), adding durvalumab to platinum/gemcitabine-based chemotherapy, before and after cystectomy, improved event-free survival and overall survival in the NIAGARA trial, with recent regulatory approval.
Immunotherapy for Platinum-ineligible Patients
For patients unsuitable for platinum-based chemotherapy, the combination of enfortumab vedotin with pembrolizumab has shown significantly improved outcomes in clinical trials and is being considered as a perioperative alternative.
Adjuvant Therapy After Cystectomy
For patients with pT3/4 or node-positive disease who did not receive neoadjuvant therapy, adjuvant platinum-based chemotherapy is recommended. In selected high-risk patients, adjuvant immunotherapy (nivolumab) is considered.
9. Preoperative Work-up
Staging
Cystoscopy with TURBT, CT scan of the chest/abdomen/pelvis with urography, laboratory assessment of kidney function.
General Preoperative Assessment
Urological and anaesthesiology assessment, evaluation of cardiovascular and thromboembolic risk, given that this is major surgery.
No Bowel Preparation
Current evidence does not support classic bowel preparation (laxatives) before the operation.
Discussion of Diversion Type
Depending on kidney function, age, cognitive/functional status and patient preference, the appropriate type of diversion is discussed before surgery.
10. How the Operation Is Performed
General Anaesthesia
The operation is performed under general anaesthesia, with the patient in a specific position.
Small Incisions
6–7 small incisions in the abdominal wall, through which the robotic instruments are introduced.
Docking the Da Vinci System
The robotic arms are connected to the access ports. The surgeon moves to the control console.
Pelvic Lymph Node Dissection
Pelvic lymph nodes are removed according to the standard template, for staging and therapeutic benefit.
Dissection & Removal of the Bladder (and adjacent organs)
The urinary bladder is freed with precision thanks to 3D magnification, together with the organs included in the operation depending on sex and stage.
Creation of Urinary Diversion
Depending on the pre-selected type, an ileal conduit, orthotopic neobladder or ureterocutaneostomy is created, either intracorporeally or with a small extraction incision (extracorporeal).
Completion
Removal of the robotic instruments, placement of drains where needed, and closure of the incisions.
The exact course differs by patient, depending on anatomy and intraoperative findings.
11. Urinary Diversion — The Three Main Types
Ileal Conduit
The most established type of diversion, with long, well-documented outcomes. A stoma is created on the abdominal wall, connected to an external urine-collection bag. It is associated with early (30-day) complications in a significant proportion of patients, mainly urinary tract infections and problems at the ureteroenteric anastomosis.
Orthotopic Neobladder
A new "reservoir" is created from a segment of small bowel and connected directly to the urethra, allowing near-normal voiding without an external bag. It is used in a meaningful proportion of well-selected patients internationally. It is contraindicated when there is invasive urethral disease, and is not routinely offered in advanced nodal disease. Oncologic outcomes are comparable to those of the ileal conduit.
Ureterocutaneostomy
The simplest technique, with shorter operative time, less blood loss and fewer complications — often preferred for older, frail patients or those with a solitary kidney, although it carries a higher risk of stomal stenosis and ascending infection compared with intestinal diversions.
There are no randomised trials directly comparing diversion types, and the type does not appear to affect oncologic outcome. The choice is individualised based on kidney function, age, functional/cognitive status and patient preference, after full information.
12. The Da Vinci Technology
The Da Vinci system consists of a surgeon console, robotic arms and an imaging system. It offers:
- Three-dimensional, magnified visualisation of the surgical field.
- Articulated instruments (EndoWrist) with a greater range of motion than the human hand.
- Filtering of natural hand tremor.
- The ability for meticulous dissection around sensitive anatomical structures such as the ureter and the neurovascular bundles.
13. Robotic vs Open Cystectomy
| Parameter | Robotic (RARC) | Open Cystectomy |
|---|---|---|
| Access | 6–7 small incisions (≤1-2 cm) | A single large lower abdominal incision |
| Blood loss | Usually lower | Usually higher |
| Operative time | Often longer | Often shorter |
| 90-day complication rate | Comparable to open approach | Comparable to robotic approach |
| Positive surgical margins | Comparable rates | Comparable rates |
| Oncologic outcomes (OS/RFS) | Depend mainly on stage & surgeon experience | Depend mainly on stage & surgeon experience |
According to systematic reviews of randomised trials, choosing an experienced surgeon/centre matters more for the final outcome than the surgical approach itself.
14. Possible Complications
Radical cystectomy is major surgery with significant overall morbidity. Possible complications include:
Prolonged postoperative ileus
Urinary tract infections / pyelonephritis
Leakage or stricture of the ureteroenteric anastomosis
Venous thromboembolic events
Delayed wound healing
Need for readmission within 30 days
Severity & Age
Patients over 80 years old show higher 90-day mortality compared with younger patients, although overall major complication rates are not necessarily higher — age alone does not automatically exclude surgery, but requires careful individualised assessment.
15. Hospital Stay & Enhanced Recovery (ERAS)
Modern Enhanced Recovery After Surgery (ERAS) protocols significantly reduce postoperative ileus and improve functional recovery after radical cystectomy, and are applied wherever feasible.
- Early mobilisation from the first postoperative day.
- Early resumption of oral intake, where safe.
- Extended venous thromboembolism prophylaxis with low-molecular-weight heparin for several weeks after discharge.
- Close monitoring of kidney function and fluid balance.
There is no single universal hospitalisation timeline for every patient — the course is individualised by the surgeon, depending on the type of diversion and clinical progress.
16. Sexual Function
Standard radical cystectomy affects sexual function, since in men the prostate and seminal vesicles are removed (with loss of normal ejaculation), and in women usually part of the vagina/uterus/ovaries.
In carefully selected, well-informed and highly motivated patients, organ-preserving techniques (prostate, capsule, nerve preservation in men; vagina, uterus, ovary preservation in women) may improve postoperative sexual function, without any guarantee of outcome, and always subject to oncologic safety.
17. What Happens After Surgery
The surgical specimen is always sent for histopathological examination, which determines the pathologic stage (pT/pN), surgical margin status and lymph node status.
Follow-up after cystectomy is two-fold — oncologic (imaging and laboratory surveillance for recurrence) and functional (kidney function, acid-base balance, vitamin B12 levels in intestinal diversions), at intervals set by the treating physician.
18. The Doctor
Dr. Marinos Vasilas, Urologist – Andrologist
Dr. Marinos Vasilas specialises in robotic surgery and 3D-4K laparoscopic surgery, with a clinical focus on urologic oncology (prostate, kidney, bladder). His training is linked to the Department of Urology of the University Hospital of Patras, following the guidelines of the European Association of Urology (EAU).
Meet the Doctor19. Surgical Team
Robotic radical cystectomy is performed in collaboration with a specialised surgical centre and urology team, ensuring access to modern robotic infrastructure for this demanding, complex operation.
Meet Our Team20. Frequently Asked Questions
What is robotic radical cystectomy?
It is the complete surgical removal of the urinary bladder (in men usually together with the prostate and seminal vesicles; in women usually together with the urethra and part of the vagina/uterus), together with pelvic lymph node dissection and creation of a new pathway for urine (urinary diversion), using the Da Vinci robotic system.
When is radical cystectomy needed rather than a smaller procedure?
Mainly for muscle-invasive bladder cancer (stage T2-T4a without distant metastases), for very high-risk non-muscle-invasive bladder cancer, or for disease that does not respond to intravesical BCG therapy (BCG-unresponsive). The decision is individualised by the urologist based on staging.
Can I avoid cystectomy with chemoradiotherapy instead?
In carefully selected patients with a solitary tumour, no extensive in-situ disease and good bladder function, trimodality bladder-preserving therapy (TURBT plus concurrent chemoradiotherapy) is a recognised alternative with comparable long-term oncologic outcomes in selected series. It requires close, lifelong bladder surveillance.
Will I need chemotherapy before the operation?
In eligible patients with muscle-invasive disease, perioperative systemic therapy is offered before or after cystectomy (e.g. platinum-based chemotherapy, or a chemo-immunotherapy/immunotherapy combination in selected cases), depending on eligibility for platinum and biopsy findings.
What is urinary diversion and what types exist?
It is the new pathway for urine after bladder removal. The main types are the ileal conduit (stoma with an external collection bag), the orthotopic neobladder (a new "bladder" built from bowel and connected to the urethra, without an external bag) and ureterocutaneostomy. The type is chosen individually.
Who is a good candidate for an orthotopic neobladder?
Patients without invasive urethral tumour, with good kidney function, good cognitive/functional status and the ability to self-catheterise if needed. It is not offered in advanced nodal disease or invaded urethra.
Will lymph nodes be removed?
Yes, pelvic lymph node dissection is an integral part of radical cystectomy, both for staging and for therapeutic benefit. Current evidence shows that a "standard" extent of lymphadenectomy offers equivalent oncologic outcomes with lower morbidity than more extended templates.
Will I lose sexual function?
In men, prostate/capsule-sparing or nerve-sparing techniques may preserve some erectile function in selected patients with localised disease, without any guarantee. In women, techniques preserving the vagina/uterus/ovaries are considered in carefully selected cases with no evidence of gynaecological malignancy. Oncologic safety always remains the priority.
How long is the hospital stay?
Length of stay varies significantly by patient and by type of urinary diversion, depending on clinical course, use of enhanced recovery (ERAS) protocols and any complications.
What are the possible complications?
Radical cystectomy is major surgery with significant overall morbidity, including ileus, urinary tract infections, leakage at the bowel/ureteral anastomosis, ureteroenteric stricture and venous thromboembolism. Risk is discussed in detail before surgery, on an individual basis.
Why is blood-thinning medication given for several weeks after surgery?
Radical cystectomy carries one of the highest venous thromboembolism risks among oncologic operations. Extended prophylaxis with low-molecular-weight heparin for several weeks after discharge is therefore recommended.
Robotic or open cystectomy — which is better?
According to randomised trials, oncologic outcomes, 90-day complication rates and surgical margin rates are comparable between robotic and open approaches. The robotic technique is often associated with lower blood loss, while choosing an experienced surgeon/centre matters more than the technique itself.
How often is follow-up needed after cystectomy?
Follow-up combines oncologic surveillance (imaging, laboratory tests) with functional monitoring of the urinary diversion (kidney function, vitamin B12, acid-base balance), at intervals set by the treating physician.
What kind of surgeon/centre is appropriate for this operation?
International literature links higher annual case volume per centre with lower mortality, lower positive margin rates and better functional outcomes. Choosing an experienced centre carries particular weight for such a complex operation.
Related Topics
Book an Appointment in Rhodes
Diagnosed with muscle-invasive bladder cancer and looking for personalised advice on treatment options? Full evaluation and staging at our clinic in Rhodes.
References
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer 2026 — uroweb.org
- Powles T, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer (NIAGARA). N Engl J Med 2024.
- Gschwend JE, et al. Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy (LEA AUO AB 25/02). Eur Urol 2019;75:604–611.
- Lerner SP, et al. Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer (SWOG S1011). N Engl J Med 2024.
The content of this page is for informational purposes only and does not replace individualised urologic/oncologic assessment. Treatment choice for bladder cancer depends on stage, kidney function, age, comorbidities and each patient's priorities.
